Eric Coldwell
Stock Analyst at Baird
(3.65)
# 753
Out of 4,670 analysts
171
Total ratings
56.31%
Success rate
4.28%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Neutral | $249 → $225 | $214.25 | +5.02% | 18 | Nov 20, 2024 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $28 → $30 | $19.73 | +52.05% | 4 | Nov 11, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $623.19 | +10.40% | 17 | Nov 7, 2024 | |
| PINC Premier | Maintains: Neutral | $19 → $20 | $22.84 | -12.43% | 6 | Nov 6, 2024 | |
| AHCO AdaptHealth | Maintains: Outperform | $16 → $14 | $9.86 | +42.06% | 9 | Nov 6, 2024 | |
| OMI Owens & Minor | Maintains: Neutral | $19 → $14 | $12.35 | +13.36% | 14 | Nov 5, 2024 | |
| IQV IQVIA Holdings | Maintains: Neutral | $256 → $223 | $201.82 | +10.49% | 14 | Nov 1, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $282 → $289 | $239.67 | +20.58% | 12 | Oct 25, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $413 → $349 | $337.75 | +3.33% | 15 | Oct 23, 2024 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $157 → $182 | $163.59 | +11.25% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $64 | $60.98 | +4.13% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $190 | $195.77 | -2.95% | 12 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $121.84 | +12.44% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $8.66 | +488.91% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $76.16 | -40.91% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $58.01 | +13.77% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.35 | +3,307.41% | 4 | Nov 10, 2017 |
ICON Public Limited Company
Nov 20, 2024
Maintains: Neutral
Price Target: $249 → $225
Current: $214.25
Upside: +5.02%
Fortrea Holdings
Nov 11, 2024
Maintains: Outperform
Price Target: $28 → $30
Current: $19.73
Upside: +52.05%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $623.19
Upside: +10.40%
Premier
Nov 6, 2024
Maintains: Neutral
Price Target: $19 → $20
Current: $22.84
Upside: -12.43%
AdaptHealth
Nov 6, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $9.86
Upside: +42.06%
Owens & Minor
Nov 5, 2024
Maintains: Neutral
Price Target: $19 → $14
Current: $12.35
Upside: +13.36%
IQVIA Holdings
Nov 1, 2024
Maintains: Neutral
Price Target: $256 → $223
Current: $201.82
Upside: +10.49%
Labcorp Holdings
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $239.67
Upside: +20.58%
Medpace Holdings
Oct 23, 2024
Downgrades: Neutral
Price Target: $413 → $349
Current: $337.75
Upside: +3.33%
Quest Diagnostics
Oct 23, 2024
Upgrades: Outperform
Price Target: $157 → $182
Current: $163.59
Upside: +11.25%
Sep 24, 2024
Downgrades: Neutral
Price Target: $64
Current: $60.98
Upside: +4.13%
Sep 20, 2024
Maintains: Neutral
Price Target: $191 → $190
Current: $195.77
Upside: -2.95%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $121.84
Upside: +12.44%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $8.66
Upside: +488.91%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $76.16
Upside: -40.91%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $58.01
Upside: +13.77%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.35
Upside: +3,307.41%